Collectively, these data suggest that PINK1 is overexpressed in olaparib-resistant cells and is associated with poor survival in advanced prostate cancer and that inhibition of PINK1 decreased cell growth and resensitized olaparib treatment. Here, PINK1 is linked to prostate carcinoma.